RemeGen Co Ltd
HKEX:9995
Intrinsic Value
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. [ Read More ]
The intrinsic value of one RemeGen Co Ltd stock under the Base Case scenario is 39.32 HKD. Compared to the current market price of 30.5 HKD, RemeGen Co Ltd is Undervalued by 22%.
Valuation Backtest
RemeGen Co Ltd
Run backtest to discover the historical profit from buying and selling RemeGen Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
RemeGen Co Ltd
Current Assets | 2.2B |
Cash & Short-Term Investments | 726.6m |
Receivables | 473.5m |
Other Current Assets | 1B |
Non-Current Assets | 3.3B |
Long-Term Investments | 98.2m |
PP&E | 3B |
Intangibles | 143.8m |
Other Non-Current Assets | 20.8m |
Current Liabilities | 1.1B |
Accounts Payable | 125.3m |
Accrued Liabilities | 224.2m |
Short-Term Debt | 301.4m |
Other Current Liabilities | 477.1m |
Non-Current Liabilities | 962.9m |
Long-Term Debt | 915.3m |
Other Non-Current Liabilities | 47.6m |
Earnings Waterfall
RemeGen Co Ltd
Revenue
|
1.1B
CNY
|
Cost of Revenue
|
-257.3m
CNY
|
Gross Profit
|
825.7m
CNY
|
Operating Expenses
|
-2.3B
CNY
|
Operating Income
|
-1.5B
CNY
|
Other Expenses
|
3.9m
CNY
|
Net Income
|
-1.5B
CNY
|
Free Cash Flow Analysis
RemeGen Co Ltd
Profitability Score
Profitability Due Diligence
RemeGen Co Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
RemeGen Co Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
RemeGen Co Ltd's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
RemeGen Co Ltd's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
RemeGen Co Ltd
According to Wall Street analysts, the average 1-year price target for RemeGen Co Ltd is 44.93 HKD with a low forecast of 40.71 HKD and a high forecast of 48.79 HKD.
Shareholder Return
Price
RemeGen Co Ltd
Average Annual Return | 0.71% |
Standard Deviation of Annual Returns | 42.75% |
Max Drawdown | -89% |
Market Capitalization | 31.6B HKD |
Shares Outstanding | 1 035 300 006 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one RemeGen Co Ltd stock under the Base Case scenario is 39.32 HKD.
Compared to the current market price of 30.5 HKD, RemeGen Co Ltd is Undervalued by 22%.